ArticleJournal of thoracic disease2025
Global bibliometric analysis of pleural mesothelioma biomarkers (2002-2024): trends and emerging frontiers.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A review of bloodstream infections-pathogens, pathogenesis, diagnostic strategies, treatment methods-challenges and future aspects.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pleural mesothelioma (PM) is an aggressive malignancy that originates on the mesothelial surface of the pleura, peritoneum, pericardium, and tunica vaginalis. Due to the absence of specific clinical symptoms, early-stage diagnosis occurs in fewer than 5% of cases. Comprehensive assessments of the research landscape on PM biomarkers remain scarce. Therefore, this study employs bibliometric methods to systematically analyze research trends and developments in PM biomarkers, delineate the historical and current research landscape, and identify emerging research frontiers. Methods: We conducted a literature search for studies on PM biomarkers published between January 1, 2002, and December 31, 2024. Bibliometric analysis and data visualization were performed using VOSviewer and CiteSpace based on literature retrieved from the Web of Science Core Collection (WoSCC). Results: A total of 662 publications on PM biomarkers, spanning from 2002 to 2024, were included in this study. Our findings reveal a substantial increase in global research on PM biomarkers over the past two decades, with annual publications peaking in 2021. The United States leads in publication volume, while the University of Western Australia ranks as the most prolific institution in this domain. Jenette Creaney, Glen Reid, and Harvey I. Pass are among the most influential authors in this field, while Conclusions: This study represents the first bibliometric visualization of the research landscape on PM biomarkers, delineating key trends and research boundaries while serving as a valuable reference for scholars.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.